Janssen Research & Development, Llc

This study tests a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma, a type of blood cancer. The goal is to see if it can make cancer undetectable in the bone marrow (called minimal residual disease negative). About 210 adults who have alr…

This phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy for adults with chronic lymphocytic leukemia (CLL) who are older or have other health issues. About 211 participants will receive either …

This study tests whether adding apalutamide to standard hormone therapy before and after prostate removal surgery can improve outcomes for men with high-risk prostate cancer. About 2,500 participants will receive either the drug or a placebo alongside hormone therapy. The goal is…